Groups
Company Size (Fulltime employees)
Looking for
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Joseph Evans United States

Pleiogenix is a clinical-stage bio-pharmaceutical company that will develop safe and effective treatments for liver and other diseases with significant unmet medical needs. The initial diseases that Pleiogenix is targeting are acute alcoholic hepatitis (AAH), COVID-19, and non-alcoholic steatohepatitis (NASH) / Fibrosis, with additional diseases to follow. AAH is a deadly liver disease resulting in mortality in most patients within 6 months, in the absence of a liver transplant. NASH is a severe form of the chronic liver disease, non-alcoholic fatty liver disease (NAFLD). The AAH market is estimated to be $575 million by 2023, while the NASH market is estimated to be $35-40 billion by 2025. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; there have been ~34 million cases resulting in over 1,000,000 deaths (globally). There are no approved therapeutics that prevent or treat AAH, NASH, or COVID-19. Pleiogenix has identified a Phase 2A-ready drug candidate, PLG888, an orally available, pan-PPAR agonist (non-thiazolidinedione) that increases circulating adiponectin without eliciting body weight gain or edema. Adiponectin is a hormone possessing significant anti-inflammatory, anti-fibrotic and metabolic clinical benefits. In patients suffering from AAH, NASH, and COVID-19, inflammation is severely increased, and adiponectin is reduced in patients with NASH. Increased adiponectin is linked to decreased systemic inflammation, increased hepatic fat oxidation, decreased hepatic fibrosis, and amelioration of NASH. Thus, PLG888 has the potential to become the first prescription pharmaceutical for AAH, NASH / fibrosis, and/or COVID-19.
Website:
www.pleiogenix.com (under construction)
Company Size (Fulltime employees)
1-10
Year of foundation
2018
Looking for
Funding Status
Currently seeking $1 million Seed funding; detailed Use of Funds / Budget available
Headquartner in China
No
Plan in China
Plan to Enter China Market 1. PLG888 will be out-licensed to a commercialization partner to serve the China Market 2. China Market can be served by a specific licensing agreement, or as part of a broader licensing Asia-targeted agreement, that includes Japan, Korea, etc; this is open for discussion. 3. Overall Out-Licensing Strategy: restricted to specific indication and by specific world area (eg North America, EU, UK, Asia); some commercialization partners might prefer worldwide commercialization rights 4. Timing: AAH and COVID-19 and Other Indications: Out-License after Phase 3 / US registration; NASH / Fibrosis: Out-License after Phase 2B (due to high cost of Phase 3 development) 5. Revenue Model for Pleiogenix: Revenues will be derived from License and Milestone payments and Royalties on sales 6. EXIT STRATEGY: Pleiogenix will be attractive acquisition target based on future revenues derived from multiple out-licensing agreements within 3-5 years. AAH and COVID-19 and Other Indications: Out-License after Phase 3 / US registration NASH / Fibrosis: Out-License after Phase 2B (due to high cost of Phase 3 development) Revenue Model for Pleiogenix Revenues will be derived from License and Milestone payments and Royalties on sales EXIT STRATEGY: Pleiogenix will be attractive acquisition target based on future revenues derived from multiple out-licensing agreements
Pleiogenix Inc.
CEO & President 
Functionality
Management

Jasper Evers Netherlands

Whale Bay & Co is a boutique financing firm focused solely on the life sciences industry. Based in Rotterdam (the Netherlands) and Basel (Switzerland) we serve SME's, investors and mid-size strategic companies in Biotech, Pharma, MedTech and Digital Health in the strategy and financial space: licensing, financing, M&A, valuation and outsources BD. We have a keen interest to expand our network and business into China. In the context of specific mandates we would like to connect with:

- pharma & medtech companies for outlicensing/JV collaborations with our clients
- investors looking for early and late stage pharma, biotech and medtech investment opportunities
- (FoF)investors interested in investment in funds
Website:
www.whalebayco.com
Company Size (Fulltime employees)
1-10
Year of foundation
2015
Looking for
Funding Status
private
Headquartner in China
No
Plan in China
Expand our network and look for partners /investors for our US and EU clients
Whale Bay & Co
Founding Partner 
Functionality
Management